Physician

Stavroula Anastasia Otis, M.D.

According to 2025 Medicare claims, Stavroula Otis, M.D. (NPI: 1477677557) practices hematology in the Anaheim-Santa Ana-Irvine, CA market, with the plurality of this provider's patient population coming from Orange, CA. This provider's primary affiliated billing organization is CENTER FOR CANCER AND BLOOD DISORDERS (NPI: 1083132625; TIN: 822604623) and primary practice location at 92868-3833.

Otis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 610 traditional Medicare patients, billed 280,089 HCPCS/CPT codes, and received $3,219,391 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 545 prescription claims across 133 beneficiaries totaling $819,368 in drug costs, led by Erleada (Apalutamide). 2021 DME data shows 11 claims. Open Payments data shows 119 records totaling $23,503. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $622,413 to $3,219,391. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	210	91,568	$622,413
2016	196	48,892	$590,334
2017	213	16,176	$321,055
2018	275	93,982	$1,402,563
2019	400	132,391	$1,736,255
2020	460	152,734	$2,684,251
2021	477	163,384	$2,402,221
2022	526	135,780	$2,040,740
2023	565	225,232	$3,012,273
2024	610	280,089	$3,219,391

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	128	747	$627,412
2016	128	934	$1,378,786
2017	144	866	$1,276,389
2018	204	1,295	$1,205,743
2019	239	1,449	$2,090,042
2020	272	1,204	$1,873,872
2021	198	815	$1,373,892
2022	180	659	$817,420
2023	178	712	$934,597
2024	133	545	$819,368

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	23	$470
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	34	$7,148
2020	N/R	N/R	N/R
2021	N/R	11	$211
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	120	120	$189
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	510	1,501	$105
96372	Injection of drug or substance under skin or into muscle	140	958	$13
36415	Insertion of needle into vein for collection of blood sample	341	1,515	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	167	1,167	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Erleada	Apalutamide	11	330	$159,469
Eliquis	Apixaban	24	870	$16,792
Anastrozole	Anastrozole	77	4,382	$1,407
Dexamethasone	Dexamethasone	20	769	$640
Prochlorperazine Maleate	Prochlorperazine Maleate	31	576	$463

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	116	$2,529	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$20,974	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Stavroula Anastasia Otis, M.D.?

Tedicare shows public-source Medicare data for Stavroula Anastasia Otis, M.D. (NPI 1477677557), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stavroula Anastasia Otis, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Stavroula Anastasia Otis, M.D.?

Stavroula Anastasia Otis, M.D. is linked to CENTER FOR CANCER AND BLOOD DISORDERS (billing NPI 1083132625) in the available physician profile data.

Does Stavroula Anastasia Otis, M.D. have Open Payments data?

Stavroula Anastasia Otis, M.D. has 119 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.